Initial characterisation of commercially available ELISA tests and the immune response of the clinically correlated SARS-CoV-2 biobank “SERO-BL-COVID-19” collected during the pandemic onset in Switzerland
Abstract
Background
To accurately measure seroprevalance in the population, both the expected immune response as well as the assay performances have to be well characterised. Here, we describe the collection and initial characterisation of a blood and saliva biobank obtained after the initial peak of the SARS-CoV-2 pandemic in Switzerland.
Methods
Two laboratory ELISAs measuring IgA & IgG (Euroimmun), and IgM & IgG (Epitope Diagnostics) were used to characterise the biobank collected from 349 re- and convalescent patients from the canton of Basel-Landschaft.
Findings
The antibody response in terms of recognized epitopes is diverse, especially in oligosymptomatic patients, while the average strength of the antibody response of the population does correlate with the severity of the disease at each time point.
Interpretation
The diverse immune response presents a challenge when conducting epidemiological studies as the used assays only detect∼90% of the oligosymptomatic cases. This problem cannot be rectified by using more sensitive assay setting as they concomitantly reduce specificity.
Funding
Funding was obtained from the “Amt für Gesundheit” of the canton Basel-Landschaft, Switzerland.
Related articles
Related articles are currently not available for this article.